Changes after publication

Changes after publication

April 2014: implementation section updated to clarify that lenalidomide is recommended as an option for treating multiple myeloma in people who have received two or more prior therapies.

February 2014: implementation section updated to clarify that lenalidomide is recommended as an option for treating multiple myeloma in people who have received at least one prior therapy. Additional minor maintenance update also carried out.

March 2012: minor maintenance

  • National Institute for Health and Care Excellence (NICE)